A Randomized, Placebo Controlled, Double Blind, Parallel Group Multi-Center Study in Order to Investigate Safety and Efficacy of CP- 690 550 in Subjects With Moderate to Severe Ulcerative Colitis.
Phase of Trial: Phase II
Latest Information Update: 01 Jan 2015
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Pfizer
- 07 Jun 2017 Biomarkers information updated
- 21 May 2013 Results reporting secondary endpoint of clinical remission presented at the Digestive Disease Week 2013.
- 16 Aug 2012 Primary endpoint 'Clinical-response-rate' has been met according to results published in the New England Journal of Medicine; more patients receiving tofacitinib 15mg bid experienced a clinical response.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History